Efficacy of Combination Therapy for Metastatic Breast Cancer Confirmed in Real-World Data Study

A new real-world data (RWD) study published in NPJ Breast Cancer has found that a combination therapy for a form of metastatic breast cancer (MBC) is more effective than monotherapy. The study investigated the use of palbociclib and an aromatase inhibitor (AI), comparing it to AI monotherapy. Data came from 2,888 patients in the Flatiron Health Analytic Database.

According to MMS Pharmacy, “The combination group were more likely to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, de novo MBC, a lower mean comorbidity score, and a higher number of metastatic sites than the monotherapy group. Patient characteristics were generally balanced following stabilized inverse probability treatment weighting (sIPTW) and between propensity score-matched groups.”

To read more, click here.

(Source: MIMS Pharmacy, October 30^th, 2022)